Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Elevated blood protein levels predict mortality

Proteins that play key roles in the development of diseases such as cancer and inflammation may...

Content from other channels on our network

Helping to keep health care professionals hands-on

Fundamental reimagining: new Sydney Children's Hospital, Randwick

A Day in the Life of a health equity consultant and street health nurse

$1bn vaccine and antivenom manufacturing facility opens

In Conversation with Australasian Institute of Digital Health CEO Anja Nikolic

Six beverage trends predicted for 2026

Mars receives final approval for its Kellanova acquisition

Making UHT processing less intensive on energy

Tasty twist for chocolate alternatives

Call for comment on endo-1,4-beta-xylanase as a processing aid

ASC certifies NT barramundi farm

NiCE advances ESG leadership

ARBS 2026 returns to Melbourne in May

First nature-related financial disclosure for university

Calls for efficiency standards for data centre water use